1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 41,340 | 41,880 | 12:58 | |
| 41,420 | 41,760 | 18.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | 174 | GlobeNewswire (Europe) | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| Mi | Gubra justiert Strategie: Wirkstoffkandidaten sollen länger im Portfolio bleiben | 21 | Investing.com Deutsch | ||
| 26.08. | Gubra A/S: Gubra announces achievement of milestone from AbbVie following initiation of a Phase 2 clinical trial of ABBV-295, a long-acting amylin analog | 350 | GlobeNewswire (Europe) | ABBV-295 is a long-acting amylin analog that represents a mechanistically distinct class from incretin-based therapies such as GLP-1 and GIP receptor agonists. Under Gubra's license agreement with AbbVie... ► Artikel lesen | |
| GUBRA Aktie jetzt für 0€ handeln | |||||
| 20.08. | Gubra H1 2026 slides: pipeline advances as CRO returns to profit | 30 | Investing.com | ||
| 20.08. | Gubra A/S: Interim report H1 2026: Strong clinical pipeline momentum and business execution position Gubra for an exciting period ahead | 670 | GlobeNewswire (Europe) | GUB-UCN2, Gubra's next potential mega program, advanced into clinical development with initiation of a comprehensive Phase 1/2a trial.Partnered obesity programs advancing into Phase 2, with Boehringer... ► Artikel lesen | |
| 28.07. | Gubra A/S: Gubra announces initiation of ambitious Phase 1/2a clinical trial of lead asset GUB-UCN2 in obesity | 551 | GlobeNewswire (Europe) | Gubra today announced the initiation of the first-in-human trial of GUB-UCN2, the company's next mega program, with the first participant completing the first visit. The ambitious Phase 1/2a clinical... ► Artikel lesen | |
| 16.07. | Gubra A/S: Boehringer Ingelheim initiates Phase 2 clinical trial of Gubra-originated triple receptor agonist for people living with overweight and obesity | 562 | GlobeNewswire (Europe) | Gubra today announces that its partner Boehringer Ingelheim has initiated a Phase 2 clinical trial of BI 3034701, an investigational, potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist... ► Artikel lesen | |
| 10.07. | Gubra A/S: Gubra collaboration partner Hemab to present preclinical results for HMB-003, a potential treatment for multiple bleeding disorders, at the ISTH 2026 Congress | 414 | GlobeNewswire (Europe) | Copenhagen, July 10, 2026: Gubra's collaboration partner Hemab will present preclinical results from the HMB-003 program on July 11, 2026, at the ISTH Congress in Paris.
The preclinical data show that... ► Artikel lesen | |
| 06.05. | Gubra Q1 2026 slides: obesity pipeline advances amid CRO headwinds | 24 | Investing.com | ||
| 06.05. | Gubra Q1 2026: Fortschritte in der Adipositas-Pipeline bei Gegenwind im CRO-Geschäft | 57 | Investing.com Deutsch | ||
| 06.05. | Gubra A/S: Trading statement Q1 2026: Continued advancement of Biotech portfolio | 693 | GlobeNewswire (Europe) | Today, Gubra releases its results for the first quarter of 2026, building on a record year in 2025. In the quarter, we advanced our Biotech business, not least shown by strong results and progress for... ► Artikel lesen | |
| 28.04. | Gubra A/S: Boehringer Ingelheim advances Gubra originated obesity triple agonist peptide into Phase 2 development | 1.001 | GlobeNewswire (Europe) | Gubra today notes that its partner Boehringer Ingelheim plans to initiate Phase 2 clinical development in mid-2026 of BI 3034701, an investigational, potential first-in-class triple GLP-1, GIP and NPY2... ► Artikel lesen | |
| 09.03. | Gubra A/S: AbbVie reports Positive Phase 1 Multiple Ascending Dose Results for ABBV-295, a Long-Acting Amylin Analog | 896 | GlobeNewswire (Europe) | Gubra's partner AbbVie today announced positive topline results from the 12 and 13-weeks Phase 1 Multiple Ascending Dose (MAD) trial showing that ABBV-295 was well tolerated with a dose-dependent significant... ► Artikel lesen | |
| 27.02. | Gubra A/S: Annual Report 2025: A record year | 947 | GlobeNewswire (Europe) | Today, Gubra releases its Annual Report for 2025 showing the strongest financial results in Gubra's history. Group revenue and operating profit amounted to DKK 2.6 billion and DKK 2.2 billion, respectively.... ► Artikel lesen | |
| 26.02. | Gubra A/S: Gubra submits clinical trial application for First-in-Human study of lead asset GUB-UCN2 | 961 | GlobeNewswire (Europe) | Gubra today announces that a clinical trial application (CTA) for the first-in-human study of GUB-UCN2, the company's lead asset for high quality weight loss, has been submitted to the Competent Authority... ► Artikel lesen | |
| 10.02. | Gubra A/S: Gubra launches Gubra Ventures and appoints Zoë Johnson to lead new venture creation unit | 476 | GlobeNewswire (Europe) | Gubra today announced the launch of Gubra Ventures, a new business unit focused on creating independent biotechnology companies from high-quality scientific innovation. Zoë Johnson has been appointed... ► Artikel lesen | |
| 08.01. | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | 545 | GlobeNewswire (Europe) | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| 05.01. | Gubra A/S: Gubra appoints Dr. Thomas Langenickel as Chief Medical and Development Officer | 627 | GlobeNewswire (Europe) | Gubra today announced the appointment of Thomas Langenickel, M.D., as Chief Medical and Development Officer (CMDO). Dr. Langenickel brings more than two decades of experience in big pharma and biotech... ► Artikel lesen | |
| 02.01. | Gubra A/S: Gubra Announces Expansion of Facilities to Support Continued Growth Across Its Businesses | 1.260 | GlobeNewswire (Europe) | Gubra A/S ("Gubra") today announced a significant expansion of its laboratory and office facilities at DTU Science Park, located in immediate proximity to the company's headquarters in Hørsholm, Denmark.... ► Artikel lesen | |
| 16.12.25 | Gubra A/S: Gubra and Camurus Enter into a Collaboration and License Agreement to Develop a Long-acting Treatment for Hypoparathyroidism | 477 | GlobeNewswire (Europe) | Gubra A/S ("Gubra"), a company specialized in peptide-based drug discovery, and Camurus AB ("Camurus"), an international, science-led biopharmaceutical company focused on developing and commercializing... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,80 | +0,18 % | Biontech-Großaktionär rechnet mit baldiger Vorstands-Neubesetzung | Mainz - Einer der Großaktionäre und Mitgründer von Biontech, Thomas Strüngmann, rechnet mit einer baldigen Neubesetzung im Vorstand des Mainzer Biotechunternehmens."Die Berufung eines neuen Medizinvorstands... ► Artikel lesen | |
| EVOTEC | 2,914 | +1,11 % | Neue Angriffspunkte gegen Krebs! Warum Vidac Pharma, BioNTech und Evotec Aufmerksamkeit verdienen! | Krebszellen nutzen ausgeklügelte Schutzmechanismen, entziehen sich dem Immunsystem und programmieren ihren eigenen Stoffwechsel um. Diese Mechanismen werden nun verstärkt zur Zielscheibe von Biotechgesellschaften.... ► Artikel lesen | |
| BB BIOTECH | 54,90 | -0,72 % | BB Biotech: KI verändert das Wie, nicht das Was | BB Biotech verbindet seit mehr als 30 Jahren wissenschaftliche Expertise mit einem konsequenten Investmentansatz im Biotechnologiesektor. Mit künstlicher Intelligenz entwickelt das Unternehmen diesen... ► Artikel lesen | |
| MEDIGENE | 0,005 | -3,70 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 38,410 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| MODERNA | 134,16 | +0,12 % | Moderna-Aktie bei 144 US$: Nächstes Hoch in Sicht? | Die Moderna-Aktie konnte gestern um +5,38% zulegen, nachdem der Kurs zuvor rund -34% korrigiert hatte. Damit zeigt sich nach dem deutlichen Rücksetzer eine erste Gegenbewegung. Nun stellt sich die entscheidende... ► Artikel lesen | |
| VALNEVA | 2,863 | +1,02 % | Valneva-Aktie im Check am 18.09. (08:01 Uhr): Meine aktuelle Lageeinschätzung | ||
| AMGEN | 335,15 | -0,16 % | Amgen: FDA Approves Update To IMDELLTRA Prescribing Information, Cuts Monitoring Time For Two Doses | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the FDA approved an update to the IMDELLTRA Prescribing Information that substantially reduces the recommended monitoring time for the first... ► Artikel lesen | |
| EPIGENOMICS | 0,900 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 8,670 | -1,37 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| STRYKER | 238,70 | -0,29 % | Stryker nach Cyberattacke: Was Anleger jetzt wissen müssen | ||
| BIOGEN | 189,04 | +0,74 % | Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN | EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based... ► Artikel lesen | |
| BIOFRONTERA | 2,360 | -3,28 % | Biofrontera erhält FDA-Zulassung für Hautkrebsbehandlung | ||
| HEIDELBERG PHARMA | 2,470 | -0,40 % | Heidelberg Pharma AG-Aktie im Check am 18.09. (08:39 Uhr): Meine aktuelle Lageeinschätzung | ||
| ILLUMINA | 210,00 | +0,70 % | Biotech Stocks At 52-Week Highs - BlossomHill Therapeutics +18% On Positive Trial Data, Adaptive Biotechnologies, Illumina, CeriBell, Neogen | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 16, 2026, driven by positive results from clinical trials or an upcoming conference participation.BlossomHill... ► Artikel lesen |
GUBRA A/S gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,05 % bei einem Aktienkurs von 41,620 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GUBRA A/S finden Sie auf Wallstreet Online.